We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+1.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$6.63B
AUM Growth
-$522M
Cap. Flow
-$72.7M
Cap. Flow %
-1.1%
Top 10 Hldgs %
50.25%
Holding
100
New
18
Increased
9
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$470M
2
TIL icon
Instil Bio
TIL
+$125M
3
MCRB icon
Seres Therapeutics
MCRB
+$85.1M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$84.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$83.1M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$312M
2
TGTX icon
TG Therapeutics
TGTX
+$195M
3
NVAX icon
Novavax
NVAX
+$157M
4
KROS icon
Keros Therapeutics
KROS
+$132M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$73.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
26
Seres Therapeutics
MCRB
$48M
$76.1M 1.15%
+184,710
New +$85.1M
SPRY icon
27
ARS Pharmaceuticals
SPRY
$528M
$76M 1.15%
1,742,186
– –
IGMS
28
DELISTED
IGM Biosciences
IGMS
$75.4M 1.14%
982,723
– –
KALA icon
29
KALA BIO
KALA
$14.1M
$73.3M 1.11%
4,354
– –
OLMA icon
30
Olema Pharmaceuticals
OLMA
$1.01B
$71.3M 1.08%
2,150,404
– –
ORTX
31
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$69.2M 1.04%
1,231,521
– –
SLDB icon
32
Solid Biosciences
SLDB
$857M
$68.4M 1.03%
824,525
+159,420
+24% +$17.6M
DSGN icon
33
Design Therapeutics
DSGN
$840M
$65.4M 0.99%
+2,186,636
New +$73.8M
BDTX icon
34
Black Diamond Therapeutics
BDTX
$101M
$62.8M 0.95%
2,589,904
– –
TRIL
35
DELISTED
Trillium Therapeutics Inc.
TRIL
$56.8M 0.86%
5,290,481
– –
PMVP icon
36
PMV Pharmaceuticals
PMVP
$63.5M
$56.3M 0.85%
1,710,265
– –
CNTB
37
Connect Biopharma Holdings
CNTB
$133M
$55.3M 0.83%
+2,991,208
New +$50.9M
CNST
38
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$52.4M 0.79%
2,238,536
+385,790
+21% +$11.7M
CCCC icon
39
C4 Therapeutics
CCCC
$399M
$51M 0.77%
1,377,569
– –
STRO icon
40
Sutro Biopharma
STRO
$419M
$48.2M 0.73%
211,821
– –
GERN icon
41
Geron
GERN
$1B
$47.6M 0.72%
30,126,299
– –
WVE icon
42
Wave Life Sciences
WVE
$1.16B
$43.6M 0.66%
7,775,207
– –
DYN icon
43
Dyne Therapeutics
DYN
$4.9B
$43.6M 0.66%
2,805,045
– –
VRNA
44
DELISTED
Verona Pharma
VRNA
$42.6M 0.64%
5,100,000
– –
ARDX icon
45
Ardelyx
ARDX
$1.21B
$40.2M 0.61%
6,077,294
-85,792
-1% -$589K
INZY
46
DELISTED
Inozyme Pharma
INZY
$39.7M 0.6%
2,003,653
– –
STSA
47
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$35M 0.53%
5,914,252
+1,232,394
+26% +$7.47M
RLAY icon
48
Relay Therapeutics
RLAY
$4.23B
$34.6M 0.52%
1,000,000
– –
AKUS
49
DELISTED
Akouos Inc
AKUS
$31.6M 0.48%
2,281,249
– –
CERE
50
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$30.2M 0.46%
2,200,000
– –
1
2
3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, RA Capital Management held 100 positions worth $6.63B, down 7.3% from $7.15B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RA Capital Management's Q1 2021 filing shows 18 new, 9 increased, 13 reduced and 18 closed positions. Its largest new stake was Vor Biopharma: 556,049 shares worth $479M. The largest sale was Arvinas, an estimated $312M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q1 2021 buy was Vor Biopharma: 556,049 shares worth $479M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q1 2021, an estimated $83.1M increase.
  • RA Capital Management's biggest Q1 2021 reduction was TG Therapeutics, cutting an estimated $195M.
  • RA Capital Management fully exited Arvinas in Q1 2021, selling an estimated $312M.
  • RA Capital Management's ten largest holdings make up 50% of its $6.63B portfolio in Q1 2021.
  • RA Capital Management opened 18 new positions and closed 18 in Q1 2021.
  • RA Capital Management's portfolio value fell 7.3% quarter-over-quarter to $6.63B.

Based on RA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.